Federal Register / Vol. 74, No. 125 / Wednesday, July 1, 2009 / Notices 31445 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Office of the National Coordinator 

for Health Information Technology 

(ONC). The meeting will be open to the 

public. 

Name of Committee: HIT Policy 

Committee. 

General Function of the Committee: to 

provide recommendations to the National 

Coordinator on a policy framework for the 

development and adoption of a nationwide 

health information technology infrastructure 

that permits the electronic exchange and use 

of health information as is consistent with 

the Federal Health IT Strategic Plan and that 

includes recommendations on the areas in 

which standards, implementation 

specifications, and certification criteria are 

needed. 

Date and Time: The meeting will be held 

on July 16, 2009, from 10 a.m. to 2 p.m./ 

Eastern Time. 

Location: The Park Hyatt Washington 

Hotel, 24th and M Streets, NW., Washington, 

DC. The hotel telephone number is 202–789– 

1234. 

Contact Person: Judy Sparrow, Office of the 

National Coordinator, HHS, 330 C Street, 

SW., Washington, DC 20201, 202–205–4528, 

Fax: 202–690–6079, e-mail: 

judy.sparrow@hhs.gov. Please call the contact 

person for up-to-date information on this 

meeting. A notice in the Federal Register 

about last minute modifications that impact 

a previously announced advisory committee 

meeting cannot always be published quickly 

enough to provide timely notice. 

Agenda: The committee will discuss the 

preliminary draft definition of Meaningful 

Use. ONC intends to make background 

material available to the public no later than 

two (2) business days prior to the meeting. 

If ONC is unable to post the background 

material on its Web site prior to the meeting, 

it will be made publicly available at the 

location of the advisory committee meeting, 

and the background material will be posted 

on ONC’s Web site after the meeting, at 

http://healthit.hhs.gov. 

Procedure: Interested persons may present 

date, information, or views, orally or in 

writing, on issues pending before the 

committee. Written submissions may be 

made to the contact person on or before July 

6, 2009. Oral comments from the public will 

be scheduled between approximately 1:30 

p.m. to 2 p.m. Time allotted for each 

presentation may be limited. If the number of 

speakers requesting to comment is greater 

than can be reasonably accommodated 

during the scheduled open public hearing 

session, ONC will take written comments 

after the meeting until close of business. 

Persons attending ONC’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

ONC welcomes the attendance of the 

public at its advisory committee meetings. 

Seating is limited at the location, and ONC 

will make every effort to accommodate 

persons with physical disabilities or special 

needs. If you require special accommodations 

due to a disability, please contact Judy 

Sparrow at least seven (7) days in advance of 

the meeting. 

ONC is committed to the orderly conduct 

of its advisory committee meetings. Please 

visit our Web site at http://healthit.hhs.gov 

for procedures on public conduct during 

advisory committee meetings. 

Notice of this meeting is given under the 

Federal Advisory Committee Act (Pub. L. No. 

92–463, 5 U.S.C., App. 2). 

Dated: June 26, 2009. 

Judith Sparrow, 

Office of Programs and Coordination, Office 

of the National Coordinator for Health 

Information Technology. 

[FR Doc. E9–15545 Filed 6–30–09; 8:45 am] 

BILLING CODE 4150–45–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Submission for OMB Review; 

Comment Request; Collection of 

Customer Service, Demographic, and 

Smoking/Tobacco Use Information 

From NCI Cancer Information Service 

(CIS) Clients (NCI) 

Summary: Under the provisions of 

Section 3507(a)(1)(D) of the Paperwork 

Reduction Act of 1995, the National 

Cancer Institute (NCI), the National 

Institutes of Health (NIH), has submitted 

to the Office of Management and Budget 

(OMB) a request to review and approve 

the information collection listed below. 

This proposed information collection 

was previously published in the Federal 

Register on May 1, 2009, (Vol. 74, No. 

83, p. 20320) and allowed 60 days for 

public comment. One public comment 

was received on May 1, 2009 requesting 

a copy of the data collection plans. An 

e-mail response was sent on May 5, 

2009, which included the Supporting 

Statements and the screenshots of the 

surveys. The purpose of this notice is to 

allow an additional 30 days for public 

comment. The National Institutes of 

Health may not conduct or sponsor, and 

the respondent is not required to 

respond to, an information collection 

that has been extended, revised, or 

implemented on or after October 1, 

1995, unless it displays a currently valid 

OMB control number. 

Proposed Collection: Title: Collection 

of Customer Service, Demographic, and 

Smoking/Tobacco Use Information from 

NCI Cancer Information Service (CIS) 

Clients (NCI) Type of Information 

Collection Request: Revision. Need and 

Use of Information Collection: The 

National Cancer Institute’s Cancer 

Information Service (CIS) provides the 

latest information on cancer, clinical 

trials, and tobacco cessation in English 

and Spanish. Clients are served by 

calling 1–800–4–CANCER for cancer 

information; 1–877–44U–QUIT for 

smoking cessations services; and using 

the NCI’s LiveHelp, a web-based chat 

service. CIS currently conducts a brief 

survey of a sample of telephone and 

LiveHelp clients at the end of usual 

service—a survey that includes three 

customer service and twelve 

demographic questions (age, sex, race, 

ethnicity, education, household income, 

number in household, and five 

questions about health care/coverage). 

Characterizing clients and how they 

found out about the CIS is essential to 

customer service, program planning, 

and promotion. The NCI also conducts 

a survey of individuals using the CIS’s 

smoking cessation services—a survey 

that includes 20 smoking/tobacco use 

‘‘intake’’ questions that serve as a needs 

assessment that addresses smoking 

history, previous quit attempts, and 

motivations to quit smoking. An 

additional question is used with callers 

who want to receive proactive call-back 

services. Responses to these questions 

enable Information Specialists to 

provide effective individualized 

counseling. Frequency of Response: 

Once. Affected Public: Individuals or 

households. Type of Respondents: 

People with cancer; their relatives and 

friends; and general public, including 

smokers/tobacco users. Annualized 

estimates for numbers of respondents 

and respondent burden are presented in 

the table below. 

Type of respondents Survey instrument Number of 

respondents 

Frequency of 

responses 

Average time 

per response 

(minutes/hour) 

Annual burden 

hours 

Telephone Clients 1

Customer Service 62,000 1 1/60 1,033.33 

Demographic Questions 22,000 1 2/60 733.33 

31446 Federal Register / Vol. 74, No. 125 / Wednesday, July 1, 2009 / Notices 

Type of respondents Survey instrument Number of 

respondents 

Frequency of 

responses 

Average time 

per response 

(minutes/hour) 

Annual burden 

hours 

Smoking Cessation ‘‘Quitline’’ Clients 1,2

Reactive Service Clients ............................ Smoking Cessation ‘‘Intake’’ 

Questions 

4,641 1 5/60 386.75 

Demographic Questions 1,300 1 2/60 43.33 

Proactive Callback Service Clients 3 .......... Follow-Up 928 4 1/60 61.87 

LiveHelp Clients 4

Demographic questions 7,014 1 2/60 233.80 

Total .................................................... .................................................. 97,883 ........................ ........................ 2524.00 

1Approximately 36% of telephone and quitline clients will be sampled for the demographic questions, and 100% of telephone clients will be 

sampled for the customer service questions. Estimates based on 77.5% response rate. 2 100% of smoking cessation clients will be asked the smoking intake questions. Estimates for quitline callers answering demographic questions are based on 77.8% response rate. 3 100% of smoking cessation clients participating in the proactive callback service (about 20% of all smoking callers) will be asked the smoking 

follow-up question (at up to 4 callbacks). 4Approximately 50% of LiveHelp clients will be sampled for the demographic questions. 

The annualized cost to the 

respondents is estimated at $48,752. 

There are no Capital Costs, Operating 

Costs, and/or Maintenance Costs to 

report. 

Request for Comments: Written 

comments and/or suggestions from the 

public and affected agencies should 

address one or more of the following 

points: (1) Evaluate whether the 

proposed collection of information is 

necessary for the proper performance of 

the function of the agency, including 

whether the information will have 

practical utility; (2) Evaluate the 

accuracy of the agency’s estimate of the 

burden of the proposed collection of 

information, including the validity of 

the methodology and assumptions used; 

(3) Enhance the quality, utility, and 

clarity of the information to be 

collected; and (4) Minimize the burden 

of the collection of information on those 

who are to respond, including the use 

of appropriate automated, electronic, 

mechanical, or other technological 

collection techniques or other forms of 

information technology. 

Direct Comments to OMB: Written 

comments and/or suggestions regarding 

the item(s) contained in this notice, 

especially regarding the estimated 

public burden and associated response 

time, should be directed to the 

Attention: NIH Desk Officer, Office of 

Management and Budget, at 

OIRA_submission@omb.eop.gov or by 

fax to 202–395–6974. To request more 

information on the proposed project or 

to obtain a copy of the data collection 

plans and instruments, contact Mary 

Anne Bright, Office of Public 

Information and Resource Management, 

Office of Communications and 

Education, National Cancer Institute, 

6116 Executive Blvd., Room 3049, MSC 

8322, Bethesda, MD 20892–8322 or call 

the non-toll-free number 301–594–9048 

or e-mail your request, including your 

address, to: brightma@mail.nih.gov. 

Comments Due Date: Comments 

regarding this information collection are 

best assured of having their full effect if 

received within 30 days of the date of 

this publication. 

Dated: June 23, 2009. 

Vivian Horovitch-Kelley, 

NCI Project Clearance Liaison, National 

Institutes of Health. 

[FR Doc. E9–15583 Filed 6–30–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

New Inhibitors of Polo-like Kinase 1 

(PLK1) as Anti-Cancer Agents 

Description of Technology: Tumor 

formation is the result of uncontrolled 

cellular growth and invasion. Polo-like 

kinase 1 (PLK1) is a regulator of cell 

growth whose overexpression has been 

associated with several types of cancer 

(e.g., breast cancer, prostate cancer, 

ovarian cancer, non-small cell lung 

carcinoma). It has been shown that 

inhibition of PLK1 causes cell death 

(apoptosis) in tumor cells but not 

normal cells. This suggested that 

inhibiting PLK1 could be an effective 

treatment for cancer patients without 

causing unwanted side-effects. 

PLK1 contains a unique protein 

domain known as the polo box domain 

(PBD), which is essential for its 

function. One strategy for inhibiting 

PLK1 involves preventing the PBD 

domain from interacting with PLK1 

substrates. A synthetic peptide with the 

ability to selectively bind to the PBD 

was recently identified. Using this 

peptide as a platform, NIH inventors 

have designed peptide mimetics that 

interact with the PBD with greater 

affinity than the wild-type peptide. By 

inhibiting PLK1 and selectively 

inducing apoptosis in cancer cells, these 

mimetics could serve as potential anticancer therapies. 

Applications: 

• New anti-cancer therapies that 

specifically target PLK1 

• Platform for the development of 

further improved PLK1 inhibitors 

Advantages: